Lipocine (LPCN) AI Stock Analysis

• Market Cap: $17.17M
• Dividend Yield: N/A
• Average Volume (3M): 21.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 14014.81%
• EPS Growth: 75.61%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.76
• Shares Outstanding: 5,347,940
• 10 Day Avg. Volume: 15,090
• 30 Day Avg. Volume: 21,712
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.17
• Price to Cash Flow (P/CF): -1.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Lipocine's overall score reflects a company in transition, with some financial recovery evident but significant challenges remaining. The strong balance sheet provides stability, yet the lack of consistent profitability and negative technical indicators weigh on the stock's prospects. Valuation concerns persist with the negative P/E ratio, and the absence of earnings call and corporate events data limits additional insights into future performance.

Lipocine Business Overview & Revenue Model

Company Description

Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men's and women's health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

How the Company Makes Money

Lipocine generates revenue primarily through licensing agreements, collaborations, and partnerships with other pharmaceutical companies. These agreements often include upfront payments, milestone payments based on development achievements, and royalties on net sales of commercialized products. Additionally, Lipocine may also secure funding through research grants and government contracts. Revenue is significantly influenced by the progress and success of its clinical trials, regulatory approvals, and the commercial launch of its product candidates.

Lipocine Financial Statement Overview

Summary

Lipocine's financial statements depict a mixed outlook. Despite strong equity and recent revenue growth, the company faces negative profitability and cash flow issues. The balance sheet is stable, but operational inefficiencies and potential liquidity challenges need to be addressed.

Income Statement

Lipocine has shown a fluctuating revenue trajectory with a significant increase in TTM revenues compared to the previous period. However, the company is struggling with negative net income and operating losses, evidenced by negative EBIT and EBITDA margins. Despite the recent revenue growth, the profitability remains a concern.

Balance Sheet

The balance sheet reflects a strong equity position with no total debt in the TTM period, resulting in a favorable debt-to-equity ratio of zero. The equity ratio remains robust, signifying a solid financial foundation. However, the company's assets have been declining, which might signal potential future liquidity issues.

Cash Flow

Lipocine's cash flow situation shows a challenging picture with negative operating and free cash flows, indicating cash burn. The free cash flow growth has improved somewhat due to reduced negative free cash flow compared to previous periods, but the overall cash flow generation remains weak, suggesting operational inefficiencies.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
7.92M	-2.85M	500.00K	16.14M	0.00	164.99K
	Gross Profit
6.05M	-2.85M	500.00K	16.14M	0.00	164.99K
	EBIT
-5.29M	-17.93M	-12.12M	3.15M	-18.00M	-12.90M
	EBITDA
-4.95M	-16.32M	-10.72M	-430.53K	-17.99M	-12.65M
	Net Income Common Stockholders
-4.06M	-16.35M	-10.76M	-634.40K	-20.96M	-13.01M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
15.25M	22.04M	32.53M	44.62M	19.67M	14.07M
	Total Assets
20.85M	23.00M	37.54M	52.48M	25.35M	19.66M
	Total Debt
10.26M	17.17K	0.00	2.31M	5.59M	7.15M
	Net Debt
2.18M	-4.75M	-3.15M	-639.73K	-13.63M	-2.58M
	Total Liabilities
11.42M	2.63M	1.91M	6.91M	10.01M	13.37M
	Stockholders Equity
9.43M	20.37M	35.63M	45.57M	15.34M	6.29M
Cash Flow		Free Cash Flow
-5.03M	-11.88M	-12.10M	-4.42M	-15.30M	-11.67M
	Operating Cash Flow
-4.95M	-11.87M	-11.97M	-4.41M	-15.30M	-11.67M
	Investing Cash Flow
4.41M	13.08M	14.29M	-43.78M	3.89M	3.00M
	Financing Cash Flow
204.04K	404.57K	-2.13M	26.92M	20.90M	10.32M

Lipocine Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LPCN, the sentiment is Negative. The current price of 3.3 is below the 20-day moving average (MA) of 3.31, below the 50-day MA of 4.01, and below the 200-day MA of 5.12, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 43.34 is Neutral, neither overbought nor oversold. The STOCH value of 41.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LPCN.

Lipocine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBIX	68 Neutral	$10.87B	33.12	14.16%	―	24.81%	33.67%
ANIP	65 Neutral	$1.38B	―	-4.86%	―	26.20%	-219.22%
Sector *	49 Neutral	$6.84B	0.05	-53.14%	2.48%	24.49%	-3.26%
LPCN	46 Neutral	$17.17M	―	-19.50%	―	14014.81%	75.61%
VKTX	42 Neutral	$3.32B	―	-17.90%	―	―	-10.27%
RDHL	41 Neutral	$3.61M	―	1155.92%	―	―	―
TXMD	33 Underperform	$8.88M	―	-14.39%	―	―	―